Holen Sie sich die Stockscreener-App
81.48
0.55%
-0.45
Handel nachbörslich:
81.48
Schlusskurs vom Vortag:
$81.93
Offen:
$82.41
24-Stunden-Volumen:
1.44M
Relative Volume:
0.80
Marktkapitalisierung:
$9.66B
Einnahmen:
$1.51B
Nettoeinkommen (Verlust:
$348.84M
KGV:
29.30
EPS:
2.7805
Netto-Cashflow:
$667.65M
1W Leistung:
+5.69%
1M Leistung:
+8.70%
6M Leistung:
+16.04%
1J Leistung:
+39.90%
1-Tages-Spanne:
$81.46
$83.50
1-Wochen-Bereich:
$76.82
$83.50
52-Wochen-Spanne:
$57.67
$83.50
Halozyme Therapeutics Inc Stock (HALO) Company Profile
Firmenname
Halozyme Therapeutics Inc
Sektor
Branche
Telefon
(858) 794-8889
Adresse
12390 EL CAMINO REAL, SAN DIEGO, CA
Compare HALO vs VRTX, REGN, ARGX, RVMD, ALNY
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
HALO
Halozyme Therapeutics Inc
|
81.48 | 9.72B | 1.51B | 348.84M | 667.65M | 2.7805 |
VRTX
Vertex Pharmaceuticals Inc
|
479.00 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
667.17 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
888.82 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.07 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.40 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Halozyme Therapeutics Inc Stock (HALO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-04 | Herabstufung | Goldman | Neutral → Sell |
| 2025-10-14 | Hochstufung | Leerink Partners | Underperform → Market Perform |
| 2025-08-06 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2025-07-10 | Fortgesetzt | Goldman | Neutral |
| 2025-05-14 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2025-05-13 | Herabstufung | Leerink Partners | Market Perform → Underperform |
| 2024-10-07 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2024-09-19 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2024-06-07 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2024-02-29 | Eingeleitet | TD Cowen | Outperform |
| 2023-07-24 | Herabstufung | Goldman | Buy → Neutral |
| 2023-07-24 | Eingeleitet | H.C. Wainwright | Buy |
| 2023-05-10 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2023-03-27 | Fortgesetzt | Berenberg | Buy |
| 2023-03-16 | Herabstufung | SVB Securities | Outperform → Market Perform |
| 2022-12-21 | Fortgesetzt | Morgan Stanley | Overweight |
| 2022-11-28 | Eingeleitet | Wells Fargo | Overweight |
| 2022-09-09 | Eingeleitet | Morgan Stanley | Overweight |
| 2022-05-23 | Eingeleitet | SVB Leerink | Outperform |
| 2021-06-14 | Eingeleitet | Evercore ISI | Outperform |
| 2021-05-17 | Eingeleitet | SVB Leerink | Outperform |
| 2021-05-11 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2021-01-21 | Bestätigt | The Benchmark Company | Buy |
| 2020-12-17 | Eingeleitet | Berenberg | Buy |
| 2020-09-14 | Fortgesetzt | JP Morgan | Overweight |
| 2020-07-01 | Eingeleitet | The Benchmark Company | Buy |
| 2020-02-05 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2020-01-09 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2020-01-08 | Eingeleitet | Goldman | Buy |
| 2019-11-05 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2018-10-19 | Fortgesetzt | Piper Jaffray | Neutral |
| 2018-05-11 | Herabstufung | Barclays | Equal Weight → Underweight |
| 2018-01-24 | Eingeleitet | Goldman | Neutral |
| 2017-10-16 | Bestätigt | Piper Jaffray | Overweight |
| 2017-01-06 | Herabstufung | Citigroup | Buy → Neutral |
| 2016-11-03 | Eingeleitet | Deutsche Bank | Buy |
| 2015-12-04 | Eingeleitet | Wells Fargo | Outperform |
| 2015-11-18 | Eingeleitet | Citigroup | Buy |
| 2015-09-22 | Eingeleitet | Barclays | Overweight |
| 2015-06-22 | Bestätigt | JP Morgan | Overweight |
| 2015-03-03 | Bestätigt | UBS | Buy |
| 2015-02-18 | Bestätigt | MLV & Co | Buy |
| 2015-01-08 | Bestätigt | MLV & Co | Buy |
Alle ansehen
Halozyme Therapeutics Inc Aktie (HALO) Neueste Nachrichten
Halozyme Therapeutics Inc (HALO) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
HALO|Halozyme Therapeutics Inc|Price:81.930|Chg%:+1.090 - TradingKey
Halozyme Therapeutics (RV7) Q3 2024 Earnings ReportResults, Call & Slides - TipRanks
Halozyme Therapeutics (HALO) Q1 2026 Earnings ReportResults, Call & Slides - TipRanks
Halozyme Therapeutics (HALO) Q4 2024 Earnings ReportResults, Call & Slides - TipRanks
Halozyme Therapeutics, Inc. Revenue Breakdown – BX:RV7 - TradingView
Halozyme Therapeutics (HALO) Q3 2025 Earnings ReportResults, Call & Slides - TipRanks
Halozyme Therapeutics (HALO) Q2 2025 Earnings ReportResults, Call & Slides - TipRanks
Halozyme Therapeutics, Inc. (HALO) Stock Price, News, Quote & History - Yahoo! Finance Canada
Halozyme Therapeutics (HALO) Q1 2025 Earnings ReportResults, Call & Slides - TipRanks
Halozyme Therapeutics, Inc. (HALO) stock price, news, quote and history - Yahoo Finance Australia
Halozyme Therapeutics (HALO) Q4 2025 Earnings ReportResults, Call & Slides - TipRanks
Halozyme Therapeutics (HALO) Q2 2024 Earnings ReportResults, Call & Slides - TipRanks
Halozyme Therapeutics, Inc. (HALO) Options Chain - Yahoo! Finance Canada
HALO5638653 Bond Profile — Key Metrics - TradingView
HALO5638653 Bond Coupon Profile — Rate & Payments - TradingView
Halozyme Therapeutics stock hits all-time high at 82.42 USD - Investing.com
Halozyme Therapeutics Inc (HALO) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Halozyme Therapeutics to report Q2 2026 results on August 6 - scanx.trade
Halozyme to host Aug. 6 call on second-quarter results - Stock Titan
Halozyme to report Q2 results after market close, host conference call - Bitget
Analysts Offer Insights on Healthcare Companies: Halozyme (HALO), Phathom Pharmaceuticals (PHAT) and Incyte (INCY) - The Globe and Mail
Halozyme Therapeutics (HALO) Lands Incyte Deal On A Valuation That Still Looks Undervalued - Sahm
Halozyme’s Partnerships, Earnings Growth See Shares Near All-Time Highs - Yahoo Finance
Should Halozyme’s New ENHANZE–Incyte Oncology Pact Reshape How HALO Investors View Its Royalty Model? - Sahm
Benchmark reiterates Halozyme stock Buy rating on Incyte deal - Investing.com UK
Benchmark reiterates Halozyme stock Buy rating on Incyte deal By Investing.com - Investing.com South Africa
Did Halozyme’s (HALO) New Incyte Enhanze Deal Just Redefine Its Precision Oncology Royalty Engine? - Yahoo Finance
HALO Inks Deal With INCY to Support Cancer Therapy Development - Yahoo Finance
Halozyme Announces Global Collaboration and License Agreement with Incyte to Support the Development of Subcutaneous Formulations of INCA033989 Using its ENHANZE Technology - marketscreener.com
HALO Reiterated by HC Wainwright & Co. -- Price Target Maintained at $95 - GuruFocus
H.C. Wainwright reiterates Incyte stock rating on Halozyme deal By Investing.com - Investing.com Canada
Halozyme (HALO) Partners with Incyte to Advance Drug Delivery Te - GuruFocus
Halozyme and Incyte sign licence agreement for INCA033989 formulations - Yahoo Finance
Halozyme Therapeutics (HALO) Secures Global Deal with Incyte for Innovative Drug Delivery - GuruFocus
Halozyme enters license agreement with Incyte - The Pharma Letter
Halozyme, Incyte to Collaborate on Development of Subcutaneous mAb Formulations - Contract Pharma
Halozyme and Incyte announce global collaboration deal - grafa.com
Halozyme Signs ENHANZE Collaboration with Incyte for Subcutaneous INCA033989 Development - Yahoo Finance
Halozyme (HALO) Partners with Incyte to Advance Drug Delivery Technology - GuruFocus
Halozyme partners with Incyte on drug delivery technology - Investing.com
Halozyme partners with Incyte on drug delivery technology By Investing.com - Investing.com South Africa
Halozyme Announces Global Collaboration and License Agreement with Incyte to Support the Development of Subcutaneous Formulations of INCA033989 Using its ENHANZE® Technology - PR Newswire
Halozyme Therapeutics, Inc. (HALO) Stock Analysis: A Booming Biotech with a 42.2% Revenue Growth - DirectorsTalk Interviews
Halozyme partners with Incyte to evaluate subcutaneous formulations - scanx.trade
Technical Reactions to HALO Trends in Macro Strategies - Stock Traders Daily
Halozyme Therapeutics (HALO) Gets A Lift As Darzalex Faspro Trial Improves Survival - Sahm
ETFs Investing in Halozyme Therapeutics, Inc. Stocks - TradingView
Halozyme Therapeutics (0J2O) Q1 2024 Earnings ReportResults, Call & Slides - TipRanks
Halozyme Therapeutics (0J2O) Q4 2025 Earnings ReportResults, Call & Slides - TipRanks
Halozyme Therapeutics (0J2O) Q3 2024 Earnings ReportResults, Call & Slides - TipRanks
Finanzdaten der Halozyme Therapeutics Inc-Aktie (HALO)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.97%
0.83%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):